Page last updated: 2024-10-17

n(g),n(g')-dimethyl-l-arginine and Dyslipidemia

n(g),n(g')-dimethyl-l-arginine has been researched along with Dyslipidemia in 12 studies

N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine

Research Excerpts

ExcerptRelevanceReference
"Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients."9.14Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010)
"In rats with dyslipidemia, atorvastatin therapy could reduce plasma level of ADMA and ADMA concentration in cardiac tissues, and these effects are associated with the dose of atorvastatin therapy."7.81Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats. ( Cai, A; Li, D; Liang, Q; Mai, W; Mai, Z; Qiu, R; Xu, R; Zeng, F; Zheng, D, 2015)
"The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear."7.80Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Saiki, Y; Shimizu, W, 2014)
"The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)."7.74Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007)
"Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL."5.40Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. ( Ercan, M; Firtina, S; Konukoglu, D, 2014)
"Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients."5.14Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010)
"In rats with dyslipidemia, atorvastatin therapy could reduce plasma level of ADMA and ADMA concentration in cardiac tissues, and these effects are associated with the dose of atorvastatin therapy."3.81Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats. ( Cai, A; Li, D; Liang, Q; Mai, W; Mai, Z; Qiu, R; Xu, R; Zeng, F; Zheng, D, 2015)
"The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear."3.80Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Saiki, Y; Shimizu, W, 2014)
"The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)."3.74Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007)
" However, poor polyphenol bioavailability and extensive metabolization restrict their applicability."2.72Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases. ( Baião, DDS; da Silva, DVT; Paschoalin, VMF; Trindade, LR, 2021)
"Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL."1.40Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. ( Ercan, M; Firtina, S; Konukoglu, D, 2014)
"Ezetimibe treatment (10mg/day) for 6 months significantly decreased circulating levels of LDL-cholesterol, triglycerides and ADMA, while it increased HDL-cholesterol levels."1.35Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. ( Adachi, H; Fujiwara, N; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2009)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's7 (58.33)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Trindade, LR1
da Silva, DVT1
Baião, DDS1
Paschoalin, VMF1
Venkatesh, R1
Srinivasan, K1
Singh, SA1
Wielkoszyński, T1
Zalejska-Fiolka, J1
Strzelczyk, JK1
Owczarek, AJ1
Cholewka, A1
Furmański, M1
Stanek, A1
Ercan, M1
Firtina, S1
Konukoglu, D1
Kohashi, K1
Nakagomi, A1
Saiki, Y1
Morisawa, T1
Kosugi, M1
Kusama, Y1
Atarashi, H1
Shimizu, W1
Zheng, D1
Liang, Q1
Zeng, F1
Mai, Z1
Cai, A1
Qiu, R1
Xu, R1
Li, D1
Mai, W1
Nakamura, T3
Sato, E3
Fujiwara, N3
Kawagoe, Y3
Ueda, Y3
Suzuki, T3
Ueda, S3
Adachi, H2
Okuda, S3
Yamagishi, S3
Yamada, S1
Takeuchi, M1
Fukami, K2
Matsui, T1
Nishiyama, Y1
Ueda, M1
Katsura, K1
Otsuka, T1
Abe, A1
Nagayama, H1
Katayama, Y1
Demirel, F1
Bideci, A1
Cinaz, P1
Camurdan, MO1
Biberoğlu, G1
Yesilkaya, E1
Hasanoğlu, A1
Schiffrin, EL1
Lipman, ML1
Mann, JF1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial[NCT00720967]Phase 3450 participants (Anticipated)Interventional2008-11-30Not yet recruiting
Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)[NCT01796418]102 participants (Anticipated)Interventional2013-03-31Recruiting
A Multicenter, Randomized Trial to Compare Xience and Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease[NCT00818792]Phase 2215 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemia

ArticleYear
Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases.
    Molecules (Basel, Switzerland), 2021, Jul-30, Volume: 26, Issue:15

    Topics: Antioxidant Response Elements; Antioxidants; Arginine; Cardiotonic Agents; Diabetes Mellitus; Drug C

2021
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007
Chronic kidney disease: effects on the cardiovascular system.
    Circulation, 2007, Jul-03, Volume: 116, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker

2007

Trials

1 trial available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemia

ArticleYear
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
    Pharmacological research, 2010, Volume: 61, Issue:1

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Arginine; Azetidines; Cholesterol; Cho

2010

Other Studies

9 other studies available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemia

ArticleYear
Effect of arginine:lysine and glycine:methionine intake ratios on dyslipidemia and selected biomarkers implicated in cardiovascular disease: A study with hypercholesterolemic rats.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 91

    Topics: Administration, Oral; Amino Acids; Animals; Arginine; Biomarkers; Body Weight; Cardiovascular Diseas

2017
Oxysterols Increase Inflammation, Lipid Marker Levels and Reflect Accelerated Endothelial Dysfunction in Experimental Animals.
    Mediators of inflammation, 2018, Volume: 2018

    Topics: Animals; Arginine; Aryldialkylphosphatase; C-Reactive Protein; Cholesterol; Dyslipidemias; Homocyste

2018
Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia.
    Clinical hemorheology and microcirculation, 2014, Volume: 57, Issue:4

    Topics: Adult; Aged; Arginine; Atherosclerosis; Biomarkers; Blood Viscosity; Dyslipidemias; Endothelium, Vas

2014
Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia.
    Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:7

    Topics: Aged; Arginine; Biomarkers; Chemokine CCL2; Chromatography, High Pressure Liquid; Chronic Disease; D

2014
Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats.
    Lipids in health and disease, 2015, May-02, Volume: 14

    Topics: Animals; Arginine; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Creatine Kinase; Dysl

2015
Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner.
    Pharmacological research, 2009, Volume: 60, Issue:6

    Topics: Adult; Arginine; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Humans; Kidney Failure,

2009
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:11

    Topics: Adult; Arginine; Cross-Sectional Studies; Dyslipidemias; Female; Glycation End Products, Advanced; H

2009
Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke.
    Journal of the neurological sciences, 2010, Mar-15, Volume: 290, Issue:1-2

    Topics: Age Factors; Aged; Arginine; Biomarkers; Blood Glucose; Brain Ischemia; Cholesterol, LDL; Dyslipidem

2010
Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
    Clinical endocrinology, 2007, Volume: 67, Issue:1

    Topics: Adolescent; Apolipoproteins B; Arginine; Biomarkers; Case-Control Studies; Cholesterol; Cholesterol,

2007